Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole.
about
CYP2C19 polymorphism influences Helicobacter pylori eradicationPharmacokinetic drug interaction profiles of proton pump inhibitors: an updateCrystallization of Esomeprazole Magnesium Water/Butanol Solvate.Proton pump inhibitor formulary considerations in the acutely ill. Part 1: Pharmacology, pharmacodynamics, and available formulations.Evaluation of the pharmacokinetic interaction between lesogaberan (AZD3355) and esomeprazole in healthy subjects.Antiplatelet drug interactions with proton pump inhibitorsDevelopment and validation of a sensitive and high-throughput LC-MS/MS method for the simultaneous determination of esomeprazole and naproxen in human plasma.Intravenous proton pump inhibitors for peptic ulcer bleeding: Clinical benefits and limits.Enantiomeric separation of proton pump inhibitors on new generation chiral columns using LC and supercritical fluid chromatography.Esomeprazole tablet vs omeprazole capsule in treating erosive esophagitis.Review of esomeprazole in the treatment of acid disorders.Pharmacologic properties of proton pump inhibitors.Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypesLiver-stage malaria parasites vulnerable to diverse chemical scaffolds.Comparison between Single-Dose Esomeprazole- and Pantoprazole-Based Triple Therapy on the Effectiveness for Helicobacter pylori Eradication in Taiwanese PopulationDaytime intragastric acid control: post hoc analyses of esomeprazole 20 mg and over-the-counter proton-pump inhibitors.Safety profile of enantiomers vs. racemic mixtures: it's the same?Pharmacokinetics and pharmacodynamics of the proton pump inhibitors.Esomeprazole: prevention and treatment of NSAID-induced symptoms and ulcers.Induction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteers.Potential options to optimize therapy of gastroesophageal reflux disease with proton pump inhibitors.Comparison of esomeprazole enteric-coated capsules vs esomeprazole magnesium in the treatment of active duodenal ulcer: a randomized, double-blind, controlled studyA case of probable esomeprazole-induced transient liver injury in a pregnant woman with hyperemesis.The pharmacology of esomeprazole and its role in gastric acid related diseases.Clinical utility of esomeprazole for treatment of gastroesophageal reflux disease in pediatric and adolescent patients.Rhabdomyolysis associated with single-dose intravenous esomeprazole administration: A case report.Clinical pharmacokinetics of fexofenadine enantiomers.CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection.Effects of CYP2C19 Genetic Polymorphisms on PK/PD Responses of Omeprazole in Korean Healthy Volunteers.Esomeprazole: potent acid suppression in the treatment of acid-related disorders.Stereoselective inhibition of cytochrome P450 forms by lansoprazole and omeprazole in vitro.Stereoselective and nonstereoselective pharmacokinetics of rabeprazole - an overview.Intra-gastric pH following single oral administrations of rabeprazole and esomeprazole: double-blind cross-over comparisonPredicting nonlinear pharmacokinetics of omeprazole enantiomers and racemic drug using physiologically based pharmacokinetic modeling and simulation: application to predict drug/genetic interactions.Simultaneous Estimation of Esomeprazole and Domperidone by UV Spectrophotometric Method.The RP-HPLC method for simultaneous estimation of esomeprazole and naproxen in binary combination.Development and validation of a DESI-HRMS/MS method for the fast profiling of esomeprazole and its metabolites in rat plasma: a pharmacokinetic study.Complexity in estimation of esomeprazole and its related impurities' stability in various stress conditions in low-dose aspirin and esomeprazole magnesium capsules.Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole.
P2860
Q27005916-D5BC9DEB-1C5D-42AD-9B82-A128DBE01E3CQ27022254-593B199D-97BF-4917-89F8-8C9156EE9CBBQ31086044-C8EA6BD3-074D-4083-A038-E04C8719BE42Q33222162-FDB96153-31ED-4088-8BAD-34F413D9D8FBQ33448993-1D29100B-F3F8-4D81-8F08-0C6109EE1BECQ33948811-C73201B6-F4DA-4276-B559-3A1F5F308829Q34618109-BE0F2C64-D2E2-4D12-810A-295CC20AC637Q34735634-2B99BBC6-2CBF-43D8-8DBE-9093F9B2E543Q34822438-4F110FE2-8D20-49B1-9F0A-AD7513CA903EQ35010994-8E68D738-A885-46D7-B7FB-0DD33AE8195FQ35058137-F0C386A9-1B7F-41A9-92A6-44D86479B754Q35572512-5EA4F2B9-9CEC-4D1E-BF9B-285C4FFE9293Q35827117-409E539A-86E2-4217-AF49-5BEA9BAD4E15Q35827444-8AF89A83-8130-4282-BA87-DE4666329DA8Q36001246-0B295A3F-BF75-4333-828C-ED37F34054CAQ36100105-A4C44740-3E38-4353-9250-A53706C1D425Q36212184-A74A105D-87CD-4B00-B84C-FD8AB87BAEC7Q36390295-92DBA235-36CD-444A-A6E5-A1A4EF1BD355Q36542670-B2BB9CA3-B6CA-43AB-8814-4419D3A28A6BQ36808048-2A188C89-9480-43FF-825B-54A3E2427F0AQ36887128-0D5B53E6-4254-4153-9D84-913378F22402Q37018462-7D15D36B-AAE9-498C-A95D-1814C45F8C91Q37237706-DEF0C920-8FD6-46F9-B33E-14B304266915Q37515629-DB675732-58C5-4B5C-81CA-69946530DCA9Q37552951-3D906196-758E-4655-99E1-F46BBDA19D39Q37561598-1E8A9DD1-F0C2-446E-8B28-021BA42A478BQ37605518-B97E2D00-8394-4B6C-ACB9-77EF55040B8DQ37641373-D249DFD6-6228-4EA0-8976-B1E583FC2866Q37646785-39C1315A-3304-4290-8B5E-CBA140BF0C64Q37740439-D5FA75D7-A323-458F-A836-6CDDD04E47DFQ37755220-6CBE4408-2A15-45F5-8A3D-D7D81A36CA68Q38514724-9D918060-2277-439F-8DD5-2E3D4873ECD4Q38907268-6FC3D671-F32E-4F24-B256-B5E1A9AF7309Q39014361-DC2B490D-D93C-42A9-848C-19FD0065FB18Q39240124-CF58A466-FE0A-49DA-A886-BABD00C085ABQ39962737-5DAB7E09-1C5A-43A7-A99E-5D53908FC661Q40830317-08993205-7B60-49AB-AA0A-0ADAB6FAE858Q41002035-67D1ED06-419A-4D17-B73C-7436EDE63AEEQ43107694-D950A69C-4E82-480C-9F5F-6C86FC36FEC4Q43742706-A945A9E2-AC9C-416A-973B-2249E9D0FFC9
P2860
Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
name
Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole.
@ast
Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole.
@en
Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole.
@nl
type
label
Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole.
@ast
Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole.
@en
Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole.
@nl
prefLabel
Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole.
@ast
Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole.
@en
Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole.
@nl
P2093
P1476
Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole.
@en
P2093
Andersson T
Hassan-Alin M
Hasselgren G
P304
P356
10.2165/00003088-200140060-00003
P577
2001-01-01T00:00:00Z
P6179
1022986056